BOSTON SCIENTIFIC CORP (BSX) vs JOHNSON & JOHNSON (JNJ)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | BSX | JNJ |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $20.07B | $94.19B |
| Revenue growth (YoY) | ▲ 19.9% | ▲ 6.0% |
| Net income | $2.9B | $26.8B |
| Gross margin | 69.0% | 67.9% |
| Diluted EPS | $1.94 | $11.03 |
| Insider net (6 mo) | −50.5K sh • 0 sells • 10 buys | −40.8K sh • 7 sells • 0 buys |
| Institutional owners | 48 | 47 |
| Institutional value held | $38.43B | $294.77B |
| Next earnings (est.) | Oct 21, 2026 | Around Jan 20, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About BOSTON SCIENTIFIC CORP (BSX)
Boston Scientific Corporation is a global medical technology company that develops, manufactures, and markets devices used across a broad range of interventional medical specialties, with a mission to transform lives through innovative medical solutions. Read more →
About JOHNSON & JOHNSON (JNJ)
Johnson & Johnson, incorporated in New Jersey in 1887, is a global healthcare holding company with approximately 138,200 full-time-equivalent employees engaged in the research, development, manufacture, and sale of a broad range of healthcare products. Read more →
Source: SEC EDGAR.